Type 2 diabetes, thiazolidinediones, and cardiovascular risk

By Taylor Clare   Hobbs FD Richard  

British Journal of General Practice, Vol. 59, Iss. 564, 2009-07 ,pp. : 520-524

Royal College of General Practitioners

Access to resources Recommend Favorite

Introduction: the role of the thiazolidinediones in the cardiovascular risk management of type 2 diabetes

By Barnett A.H.  

Current Medical Research and Opinion, Vol. 21, Iss. 3, 2005-03 ,pp. : 1-4

Informa Healthcare

Access to resources Recommend Favorite

Atrial electromechanical delay in type 2 diabetes mellitus

By Akyel Ahmet   Öksüz Fatih   Karadeniz Muhammed   Yarlıoğlueş Mikail   Ergün Gökhan   Cankurt Tayyar   Yozgat Ahmet   Keskin Arıel Müge   Aral Yalçın   Murat Sani Namık  

Wiener klinische Wochenschrift, Vol. 126, Iss. 3-4, 2014-02 ,pp. : 101-105

Springer Publishing Company

Access to resources Recommend Favorite

Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone

By  

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 234-244

Bentham Science Publishers

Access to resources Recommend Favorite

Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 8, 2015-08 ,pp. : 871-882

John Wiley & Sons Inc

Access to resources Recommend Favorite